Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
27 studies found for:    DPYD
Show Display Options
Rank Status Study
1 Active, not recruiting Association of Dihydropyrimidine Dehydrogenase (DPYD) Variants With Toxicity Related to Capecitabine
Condition: Breast Cancer
Intervention: Procedure: Phlebotomy
2 Completed Pharmacogenomic and Pharmacokinetic Safety and Cost-saving Analysis in Patients Treated With Fluoropyrimidines
Condition: Neoplasms
Intervention: Drug: Capecitabine, 5-fluorouracil
3 Completed Pharmacology-driven Dosing of Fluoropyrimidines in Cancer Patients
Condition: Colorectal Cancer
Interventions: Other: 5FU and capecitabine (Xeloda®) dosing based on DPYD genotype;   Other: Therapeutic drug monitoring of 5FU
4 Recruiting Safety, Feasibility and Cost-effectiveness of Genotype-directed Individualized Dosing of Fluoropyrimidines
Condition: Neoplasms
Intervention: Drug: Fluoropyrimidine (capecitabine or 5-fluorouracil)
5 Recruiting Food-effect Study on Uracil and Dihydrouracil Levels as a Diagnostic Marker of Dihydropyrimidine Dehydrogenase Activity
Condition: Drug Safety Biomarkers
Intervention: Other: Test meal (breakfast)
6 Completed A Study of ADH300004 in Surgically Resected Primary or Metastatic Colorectal Cancer and Liver Biopsy, or Planned Hepatic Resection
Condition: Neoplasms
Intervention: Drug: ADH300004
7 Unknown  Pre-therapeutic Identification of Dihydropyrimidine Dehydrogenase Gene (DPD) Deficiency for Predicting Toxicity to Fluoropyrimidines
Conditions: Colorectal Cancer;   Intravenous 5 Fluorouracile
Intervention: Genetic: Blood sample for phenotypic and pharmacogenetic analysis.
8 Recruiting Study of DPD for Predicting Efficacy and Safety to S-1 Plus Oxaliplatin in Gastrointestinal Cancer
Condition: Gastrointestinal Cancer
Intervention: Drug: S-1 plus oxaliplatin
9 Suspended A Study of 5 Fluorouracil and the Anti-Tumor Activity of ADH300004 and 5 Fluorouracil in Subjects With Incurable Solid Tumors
Condition: Neoplasms
Intervention: Drug: ADH300004
10 Terminated A Study of ADH300004 and 5-Fluorouracil in Locally Advanced, Recurrent, or Metastatic Hepatocellular Carcinoma
Condition: Hepatocellular Carcinoma
Intervention: Drug: ADH300004
11 Completed Eniluracil and Surgery in Treating Patients With Primary or Metastatic Colorectal Cancer
Condition: Colorectal Cancer
Interventions: Drug: eniluracil;   Procedure: conventional colon surgery
12 Completed Predicting Response to Capecitabine in Women With Metastatic Breast Cancer
Condition: Breast Cancer
Interventions: Drug: capecitabine;   Other: laboratory biomarker analysis;   Other: pharmacological study
13 Completed A Phase 1, Open-Label, Randomized, Cross-Over, Pharmacokinetic Study Evaluating the Effect of S-1 on Advanced Solid Tumors
Condition: Tumors
Interventions: Drug: S-1;   Drug: FT
14 Completed A Phase I Trial of 5-Fluorouracil Given With 776C85 (GW776) and Low-Dose Leucovorin in Adult Patients With Solid Tumors
Conditions: Lymphoma;   Neoplasms
Interventions: Drug: 5-Fluorouracil;   Drug: Ethynyluracil;   Drug: Leucovorin
15 Unknown  Study of S1 Efficacy and Toxicity as Second-line Treatment on Inoperable or Advanced Gastric Cancers
Condition: Gastric Cancer
Intervention:
16 Active, not recruiting Adjuvant Hepatic Arterial Infusion and Combination Chemotherapy in Treating Patients With Resectable Hepatic Metastases From Colorectal Cancer
Conditions: Colorectal Cancer;   Metastatic Cancer
Interventions: Drug: FOLFOX regimen;   Drug: dexamethasone;   Drug: floxuridine;   Drug: fluorouracil;   Drug: leucovorin calcium;   Drug: oxaliplatin;   Procedure: adjuvant therapy;   Procedure: conventional surgery
17 Unknown  Study of S-1 as Second Line Treatment on Advanced Pancreatic Cancers
Condition: Pancreatic Cancer
Interventions: Drug: S-1;   Drug: S-1 plus Leucovorin
18 Unknown  Pharmacokinetic and Pharmacodynamic Study of S-1 in Patients With Digestive Organ Cancer
Conditions: Gastric Cancer;   Esophageal Cancer;   Pancreatic Cancer;   Colon Cancer
Intervention: Drug: S-1
19 Not yet recruiting Neoadjuvant ECS Versus ECF in Local Advanced Breast Cancer
Conditions: Breast Neoplasms;   Neoadjuvant Therapy
Interventions: Drug: S-1;   Drug: 5-FU
20 Completed Biweekly Versus Triweekly Raltitrexed With Oxaliplatin (With or Without Bevacizumab) in First-line Metastatic Colorectal Cancer
Condition: Metastatic Colorectal Cancer
Interventions: Drug: TOMOX;   Drug: Bevacizumab

   Previous Page Studies Shown (1-20) Next Page (21-27) Show next page of results    Last Page
Indicates status has not been verified in more than two years